Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
- Status
- UNKNOWN
- Phase
- PHASE1
Clinical Trials Related to Triple Negative Breast Cancer
Related studies linked through entity extraction aliases.
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
- Status
- COMPLETED
- Phase
- PHASE3
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
PCA062 in pCAD-positive Tumors.
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
- Status
- TERMINATED
- Phase
- PHASE2
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
- Status
- TERMINATED
- Phase
- PHASE1
Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE1
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
- Status
- COMPLETED
- Phase
- PHASE1
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2